Department of Dermatology, Hiratsuka City Hospital, Hiratsuka, Japan.
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
J Dermatol. 2021 Aug;48(8):1262-1267. doi: 10.1111/1346-8138.15914. Epub 2021 Apr 25.
Topical imiquimod therapy has been widely used for actinic keratosis (AK). However, some cases are refractory to treatment. Therefore, an indicator that can predict its efficacy is desired. Herein, we retrospectively analyzed 52 AK lesions treated with imiquimod to investigate the characteristics of refractory lesions. Imiquimod was applied in a cycle of three times weekly for 4 weeks, followed by a 4-week break. This treatment cycle was repeated up to three times and treatment responses were evaluated. As a result, a complete response (CR) was observed in 78.8% (41/52) of lesions. Next, treatment response of lesions was correlated with clinicopathological characteristics including clinical morphology and thickness, pathological morphology and thickness, and presence of follicular extension (FE). Of these, lesions with FE were significantly less responsive to imiquimod treatment; while 92.6% of AK lesions without FE achieved a CR, only 64.0% of AK lesions with FE achieved a CR (p = 0.029). Logistic regression analysis revealed that FE was the sole significant predictor of its efficacy (p = 0.019). These results suggest that preliminary histological evaluation of FE may be useful to predict the efficacy of imiquimod for AK.
咪喹莫特局部治疗已广泛用于光化性角化病(AK)。然而,有些病例对治疗有抗性。因此,需要一种可以预测其疗效的指标。在此,我们回顾性分析了 52 例接受咪喹莫特治疗的 AK 病变,以探讨难治性病变的特征。咪喹莫特每周应用 3 次,持续 4 周,然后休息 4 周。该治疗周期最多重复 3 次,并评估治疗反应。结果,78.8%(41/52)的病变完全缓解(CR)。接下来,将病变的治疗反应与临床病理特征相关联,包括临床形态和厚度、病理形态和厚度以及滤泡延伸(FE)的存在。其中,有 FE 的病变对咪喹莫特治疗的反应明显较差;而无 FE 的 AK 病变 92.6%达到 CR,仅有 FE 的 AK 病变 64.0%达到 CR(p=0.029)。逻辑回归分析显示,FE 是其疗效的唯一显著预测因素(p=0.019)。这些结果表明,FE 的初步组织学评估可能有助于预测咪喹莫特治疗 AK 的疗效。